Ionis Pharmaceuticals, Inc. (IONS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $166.00K; Additional Paid in Capital, Common StockUSD $3.31B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-33.90M; Retained Earnings (Accumulated Deficit)USD $-2.84B.
- 2026-03-31: Common Stock, Value, IssuedUSD $166.00K; Additional Paid in Capital, Common StockUSD $3.25B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-31.02M; Retained Earnings (Accumulated Deficit)USD $-2.72B.
- 2025-12-31: Common Stock, Value, IssuedUSD $163.00K; Additional Paid in Capital, Common StockUSD $3.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-25.28M; Retained Earnings (Accumulated Deficit)USD $-2.63B.
- 2025-09-30: Common Stock, Value, IssuedUSD $161.00K; Additional Paid in Capital, Common StockUSD $3.05B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-25.98M; Retained Earnings (Accumulated Deficit)USD $-2.40B.
Ionis Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | APIC, Share-based Payment Arrangement, Recognition and Exercise USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $166.00K | $3.31B | $-33.90M | $-2.84B | $439.74M | 3 month · $45.59M 6 month · $88.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $166.00K | $3.25B | $-31.02M | $-2.72B | $491.41M | 3 month · $43.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $163.00K | $3.15B | $-25.28M | $-2.63B | $489.09M | 12 month · $135.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $161.00K | $3.05B | $-25.98M | $-2.40B | $617.97M | 3 month · $31.58M 9 month · $91.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $159.00K | $2.93B | $-27.99M | $-2.27B | $631.72M | 3 month · $30.20M 6 month · $60.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $159.00K | $2.90B | $-28.95M | $-2.40B | $475.73M | 3 month · $30.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $158.00K | $2.87B | $-30.81M | $-2.25B | $588.35M | 12 month · $131.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $158.00K | $2.83B | $-24.17M | $-2.15B | $662.47M | 3 month · $32.49M 9 month · $94.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $146.00K | $2.30B | $-34.84M | $-2.00B | $263.70M | 3 month · $30.73M 6 month · $62.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $146.00K | $2.27B | $-34.96M | $-1.94B | $296.51M | 3 month · $31.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $144.00K | $2.22B | $-32.65M | $-1.80B | $386.69M | 12 month · $105.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $143.00K | $2.15B | $-46.04M | $-1.79B | $315.46M | 3 month · $25.96M 9 month · $79.47M | $315.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $143.00K | $2.12B | $-50.91M | $-1.64B | $428.30M | 3 month · $26.56M 6 month · $53.51M | $428.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $143.00K | $2.09B | $-48.98M | $-1.55B | $486.57M | 3 month · $26.95M | $486.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $142.00K | $2.06B | $-57.48M | $-1.43B | $572.89M | 12 month · $100.26M | $572.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $142.00K | $2.03B | $-63.14M | $-1.38B | $594.36M | 3 month · $23.84M 9 month · $74.58M | $594.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $142.00K | $2.01B | $-54.01M | $-1.33B | $624.73M | 3 month · $24.50M 6 month · $50.74M | $624.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $142.00K | $1.98B | $-48.58M | $-1.23B | $709.57M | 3 month · $26.24M | $709.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $141.00K | $1.96B | $-32.67M | $-1.16B | $771.74M | 12 month · $120.68M | $771.74M | (m) | (m) | 12 month · $89.75M | 12 month · $-136.62M | (m) | (m) | (m) |
| 2021-09-30 | $141.00K | $1.94B | $-27.44M | $-1.38B | $530.54M | 3 month · $30.54M 9 month · $98.42M | $530.54M | (m) | (m) | 3 month · $0.00 9 month · $89.75M | 3 month · $0.00 9 month · $-136.62M | (m) | (m) | (m) |
| 2021-06-30 | $141.00K | $1.91B | $-25.80M | $-1.30B | $582.67M | 3 month · $30.02M 6 month · $67.88M | $582.67M | (m) | (m) | 3 month · $89.75M 6 month · $89.75M | 3 month · $-136.62M 6 month · $-136.62M | (m) | (m) | (m) |
| 2021-03-31 | $141.00K | $1.93B | $-24.20M | $-1.22B | $680.56M | 3 month · $37.86M | $680.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $140.00K | $1.90B | $-21.07M | $-1.13B | $743.28M | 12 month · $230.12M | $743.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $140.00K | $2.31B | $-19.57M | $-909.10M | $1.38B | 3 month · $45.84M 9 month · $135.08M | $1.52B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $139.00K | $2.27B | $-16.44M | $-878.15M | $1.38B | 3 month · $48.44M 6 month · $89.23M | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $139.00K | $2.23B | $-27.23M | $-846.31M | $1.36B | 3 month · $40.79M | $1.47B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $140.00K | $2.20B | $-25.29M | $-707.53M | $1.47B | 12 month · $146.57M | $1.58B | 12 month · $81.88M | (m) | 12 month · $56.11M | 12 month · $-85.86M | (m) | 12 month · $-19.24M | (m) |
| 2019-09-30 | $141.00K | $2.22B | $-25.38M | $-857.56M | $1.34B | 3 month · $24.13M 9 month · $111.56M | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $140.00K | $2.18B | $-24.25M | $-883.73M | $1.27B | 3 month · $41.93M 6 month · $87.44M | $1.46B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $140.00K | $2.12B | $-27.61M | $-882.85M | $1.21B | 3 month · $45.51M | $1.39B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $138.00K | $2.05B | $-32.02M | $-967.29M | $1.05B | 12 month · $131.31M | $1.10B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $138.00K | $2.03B | $-32.53M | $-1.29B | $710.55M | 3 month · $34.88M 9 month · $97.21M | $840.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $137.00K | $2.01B | $-32.63M | $-1.28B | $696.25M | 3 month · $33.88M 6 month · $62.33M | $817.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $125.00K | $1.58B | $-33.23M | $-1.24B | $301.39M | 3 month · $28.45M | $387.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $125.00K | $1.55B | $-31.76M | $-1.24B | $281.01M | 12 month · $85.97M | $365.28M | (m) | (m) | (m) | (m) | 12 month · $30.00K | (m) | (m) |
| 2017-09-30 | $125.00K | $1.53B | $-30.20M | $-1.19B | $307.97M | (m) | $397.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $124.00K | $1.43B | $-30.37M | $-1.19B | $215.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $124.00K | $1.41B | $-30.46M | $-1.18B | $201.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $122.00K | $1.31B | $-30.36M | $-1.18B | $99.56M | 12 month · $72.11M | $39.61M | 12 month · $43.34M | (m) | (m) | (m) | (m) | (m) | 12 month · $1.86M |
| 2016-09-30 | $121.00K | $1.37B | $-26.50M | $-1.21B | $139.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $121.00K | $1.35B | $-26.85M | $-1.21B | $111.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $121.00K | $1.33B | $-16.11M | $-1.16B | $158.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $120.00K | $1.31B | $-13.56M | $-1.09B | $200.79M | 12 month · $59.31M | $200.79M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $396.00K |
| 2015-09-30 | $120.00K | $1.29B | $-17.96M | $-1.02B | $245.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $120.00K | $1.27B | $18.41M | $-987.66M | $300.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $120.00K | $1.25B | $47.11M | $-1.02B | $275.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $118.00K | $1.22B | $39.75M | $-1.01B | $257.78M | 12 month · $31.38M | $257.78M | 12 month · $170.23M | (m) | (m) | (m) | (m) | (m) | 12 month · $1.46M |
| 2014-09-30 | $118.00K | $1.37B | $16.89M | $-1.04B | $344.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $118.00K | $1.35B | $24.72M | $-1.01B | $366.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $118.00K | $1.34B | $29.00M | $-998.89M | $374.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $116.00K | $1.32B | $21.08M | $-967.61M | $378.39M | 12 month · $11.42M | $378.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $116.00K | $1.32B | $29.02M | $-943.33M | $401.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $114.00K | $1.29B | $26.99M | $-918.76M | $401.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $103.00K | $1.09B | $17.78M | $-908.64M | $201.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $102.00K | $1.08B | $12.48M | $-906.97M | $182.77M | 12 month · $8.57M | $182.77M | 12 month · $57.56M | 12 month · $12.04M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $102.00K | $1.07B | $846.00K | $-904.33M | $170.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $100.00K | $1.02B | $968.00K | $-866.69M | $154.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $100.00K | $1.02B | $-242.00K | $-865.48M | $150.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $100.00K | $1.01B | $-770.00K | $-841.49M | $171.43M | 12 month · $9.85M | $171.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | $100.00K | $1.01B | $-1.15M | $-821.45M | $186.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $100.00K | $1.01B | $399.00K | $-794.57M | (m) | (m) | $212.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $100.00K | $1.00B | $689.00K | $-776.68M | (m) | (m) | $227.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $99.00K | $1.00B | $949.00K | $-756.69M | $244.54M | 12 month · $12.16M | $244.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $99.00K | $995.15M | $1.16M | $-742.70M | $253.71M | (m) | $253.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $99.00K | $991.44M | $941.00K | $-730.25M | $262.23M | (m) | $262.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $99.00K | $985.62M | $2.15M | $-696.15M | $291.72M | 12 month · $11.83M | $302.06M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $278.00K |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | 12 month · $15.06M | $147.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $59.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |